158 related articles for article (PubMed ID: 31926247)
1. Antitumor effects of rafoxanide in diffuse large B cell lymphoma via the PTEN/PI3K/Akt and JNK/c-Jun pathways.
He W; Xu Z; Song D; Zhang H; Li B; Gao L; Zhang Y; Feng Q; Yu D; Hu L; Chen G; Tao Y; Wu X; Shi J; Zhu W
Life Sci; 2020 Feb; 243():117249. PubMed ID: 31926247
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.
Ma Y; Zhang P; Gao Y; Fan H; Zhang M; Wu J
Int J Clin Exp Pathol; 2015; 8(11):14875-84. PubMed ID: 26823817
[TBL] [Abstract][Full Text] [Related]
3. Anti-DLBCL efficacy of DCZ0825 in vitro and in vivo: involvement of the PI3K‒AKT‒mTOR/JNK pathway.
Hu K; Li B; Ma R; Yi H; Xu Z; Peng Y; Yu D; Wu H; Cheng T; Lu Y; Zhang Y; Wei R; Yang G; Wu X; Zhu W; Shi J
Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):575-583. PubMed ID: 33821934
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
[TBL] [Abstract][Full Text] [Related]
6. DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.
Sun X; Li B; Xie B; Xu Z; Chang G; Tao Y; Zhang Y; Chang S; Wang Y; Yu D; Xie Y; Li T; Wang H; Chen G; Hu L; Hou J; Zhang Y; Xiao W; Gao L; Shi J; Zhu W
Cell Death Dis; 2017 Oct; 8(10):e3111. PubMed ID: 29022919
[TBL] [Abstract][Full Text] [Related]
7. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
[TBL] [Abstract][Full Text] [Related]
8. Rafoxanide promotes apoptosis and autophagy of gastric cancer cells by suppressing PI3K /Akt/mTOR pathway.
Liu JZ; Hu YL; Feng Y; Guo YB; Liu YF; Yang JL; Mao QS; Xue WJ
Exp Cell Res; 2019 Dec; 385(2):111691. PubMed ID: 31678170
[TBL] [Abstract][Full Text] [Related]
9. ROS play an important role in ATPR inducing differentiation and inhibiting proliferation of leukemia cells by regulating the PTEN/PI3K/AKT signaling pathway.
Feng Y; Hua X; Niu R; Du Y; Shi C; Zhou R; Chen FH
Biol Res; 2019 May; 52(1):26. PubMed ID: 31053167
[TBL] [Abstract][Full Text] [Related]
10. Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway.
Xiao W; Xu Z; Chang S; Li B; Yu D; Wu H; Xie Y; Wang Y; Xie B; Sun X; Kong Y; Lan X; Bu W; Chen G; Gao L; Wu X; Shi J; Zhu W
Cancer Lett; 2019 Mar; 444():45-59. PubMed ID: 30583070
[TBL] [Abstract][Full Text] [Related]
11. Reactive oxygen species mediate oridonin-induced apoptosis through DNA damage response and activation of JNK pathway in diffuse large B cell lymphoma.
Xu ZZ; Fu WB; Jin Z; Guo P; Wang WF; Li JM
Leuk Lymphoma; 2016; 57(4):888-98. PubMed ID: 26415087
[TBL] [Abstract][Full Text] [Related]
12. Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway.
Wu C; Chen S; Wu Z; Xue J; Zhang W; Wang S; Xindong Zhao ; Wu S
J Cancer Res Clin Oncol; 2024 Feb; 150(2):98. PubMed ID: 38381215
[TBL] [Abstract][Full Text] [Related]
13. Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.
Redondo-Muñoz J; Escobar-Díaz E; Hernández Del Cerro M; Pandiella A; Terol MJ; García-Marco JA; García-Pardo A
Clin Cancer Res; 2010 Sep; 16(17):4382-91. PubMed ID: 20534739
[TBL] [Abstract][Full Text] [Related]
14. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
[TBL] [Abstract][Full Text] [Related]
15. DCZ3301, a novel aryl-guanidino inhibitor, induces cell apoptosis and cell cycle arrest via suppressing the PI3K/AKT pathway in T-cell leukemia/lymphoma.
Xiao W; Li B; Sun X; Yu D; Xie Y; Wu H; Chang S; Zhou Y; Wang H; Lan X; Xu Z; Shi J; Zhu W
Acta Biochim Biophys Sin (Shanghai); 2018 Jul; 50(7):643-650. PubMed ID: 29688264
[TBL] [Abstract][Full Text] [Related]
16. Glaucocalyxin A induces G2/M cell cycle arrest and apoptosis through the PI3K/Akt pathway in human bladder cancer cells.
Lin W; Xie J; Xu N; Huang L; Xu A; Li H; Li C; Gao Y; Watanabe M; Liu C; Huang P
Int J Biol Sci; 2018; 14(4):418-426. PubMed ID: 29725263
[TBL] [Abstract][Full Text] [Related]
17. Impact of MAPK and PI3K/AKT signaling pathways on Malabaricone-A induced cytotoxicity in U937, a histiocytic lymphoma cell line.
Manna A; De Sarkar S; De S; Bauri AK; Chattopadhyay S; Chatterjee M
Int Immunopharmacol; 2016 Oct; 39():34-40. PubMed ID: 27398613
[TBL] [Abstract][Full Text] [Related]
18. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
[No Abstract] [Full Text] [Related]
19. Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways.
Zhang L; Huo X; Liao Y; Yang F; Gao L; Cao L
Sci Rep; 2017 May; 7(1):1669. PubMed ID: 28490807
[TBL] [Abstract][Full Text] [Related]
20. SPAG6 promotes cell proliferation and inhibits apoptosis through the PTEN/PI3K/AKT pathway in Burkitt lymphoma.
Zhang R; Zhu H; Yuan Y; Wang Y; Tian Z
Oncol Rep; 2020 Nov; 44(5):2021-2030. PubMed ID: 33000212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
